IL6 and rheumatoid arthritis: Use of this drug (tocilixumab) in phase II clinical trials for rheumatoid arthritis has proved the clinical benefit of IL-6 blockade and we suggest that such a strategy should be applied to hormone-refractory (Nishimoto and Kishimoto, 2006).